Menu

Pipeline Overview*

PRODUCT2 Indication Pre-clinical Phase 1/2 Phase 3 Marketed
Donnatal® IBS and acute enterocolitis3
U.S. CO-PROMOTION
Mytesi® Non-infectious diarrhea in HIV/AIDS patients4
U.S. CO-PROMOTION
EnteraGam® Chronic diarrhea and loose stools5
U.S. EXCLUSIVE LICENSE
Esomeprazole Strontium DR Capsules GERD and other GI conditions6
U.S. COMMERCIALIZATION LICENSE
Talicia®
(RHB-105)
H. pylori infections
RHB-104 Crohn's disease
RHB-204 NTM infections
Bekinda®
(RHB-102)
Gastroenteritis & gastritis
IBS-D
RHB-106 Bowel cleanser
Yeliva® (ABC294640) Multiple indications
RHB-107 (MESUPRON) Oncology/GI
Other
RIZAPORT®
(RHB-103)
Migraine
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies ; 2 Bekinda®, Yeliva® and Talicia® are proposed tradenames which are subject to FDA review and approval 3 For full prescribing information see: www.Donnatal.com; 4 Mytesi® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). For full prescribing information see: www.Mytesi.com 5 EnteraGam® (serum-derived bovine immunoglobulin/protein isolate, SBI) is a medical food which must be administered under medical supervision

Company Profile

RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company primarily focused on development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases.

Read more